mouse anti human c5 Search Results


monoclonal mouse anti human c5 9 antibodies  (Bio-Rad)
92
Bio-Rad monoclonal mouse anti human c5 9 antibodies
(A) Complement <t>C5-9</t> fixation on CS2 pRBCs was tested by flow cytometry following opsonization with either antibodies from a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs) or 6 Australian malaria non-exposed donors in the presence of NS. Complement fixation is presented as the average gMFI of each sample tested in duplicate and the red line represents the median gMFI for all samples tested in each category. (B) Correlation between complement C5-9 fixation and C1q/C3 fixation tested on a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs). (C) Complement-mediated pRBC killing/lysis was examined by culturing CS2 pRBCs opsonized with antibodies from PNG pregnant women (n=7) in the presence of normal serum, heat-inactivated serum or no-added serum and measuring parasitaemia by flow cytometry after two growth cycles. Data are presented as the average parasitaemia of each sample run in triplicate over 3 independent experiments. The dotted red line represents the median parasitaemia of CS2 pRBCs cultured in the absence of either PNG or Australian malaria non-exposed antibodies and NS or HIS. Comparisons were made using Mann-Whitney U-test.
Monoclonal Mouse Anti Human C5 9 Antibodies, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+c5/Mouse+anti+Human+C5/med_rxiv__2021__06__02__21258254-85-58-85
Average 92 stars, based on 1 article reviews
monoclonal mouse anti human c5 9 antibodies - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
lgm-eculizumab, a humanized, mouse anti-human c5 monoclonal antibody (1.02 μm–1.63 nm, lgmpharma; nashville, tn)  (LGM Pharma)
90
LGM Pharma lgm-eculizumab, a humanized, mouse anti-human c5 monoclonal antibody (1.02 μm–1.63 nm, lgmpharma; nashville, tn)
(A) Complement <t>C5-9</t> fixation on CS2 pRBCs was tested by flow cytometry following opsonization with either antibodies from a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs) or 6 Australian malaria non-exposed donors in the presence of NS. Complement fixation is presented as the average gMFI of each sample tested in duplicate and the red line represents the median gMFI for all samples tested in each category. (B) Correlation between complement C5-9 fixation and C1q/C3 fixation tested on a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs). (C) Complement-mediated pRBC killing/lysis was examined by culturing CS2 pRBCs opsonized with antibodies from PNG pregnant women (n=7) in the presence of normal serum, heat-inactivated serum or no-added serum and measuring parasitaemia by flow cytometry after two growth cycles. Data are presented as the average parasitaemia of each sample run in triplicate over 3 independent experiments. The dotted red line represents the median parasitaemia of CS2 pRBCs cultured in the absence of either PNG or Australian malaria non-exposed antibodies and NS or HIS. Comparisons were made using Mann-Whitney U-test.
Lgm Eculizumab, A Humanized, Mouse Anti Human C5 Monoclonal Antibody (1.02 μm–1.63 Nm, Lgmpharma; Nashville, Tn), supplied by LGM Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+c5/lgm+eculizumab++a+humanized++mouse+anti+human+c5+monoclonal+antibody++1+02+%CE%BCm+1+63+nm++lgmpharma++nashville++tn+/pm29156357-63-23-34
Average 90 stars, based on 1 article reviews
lgm-eculizumab, a humanized, mouse anti-human c5 monoclonal antibody (1.02 μm–1.63 nm, lgmpharma; nashville, tn) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mouse anti-human alpp (4e9-c5-e10) [+biotin]  (RayBiotech)
N/A
Mouse anti-Human ALPP (4E9-C5-E10) [+Biotin] Antibody, 50 ug
   Buy from Supplier
mouse anti-human alpp (4e9-c5-e10)  (RayBiotech)
N/A
Mouse anti-Human ALPP (4E9-C5-E10) Antibody
   Buy from Supplier
mouse anti-human fabp3 [+biotin] (1e5-c5-g10)  (RayBiotech)
N/A
Mouse anti-Human FABP3 Biotinylated Antibody, 50 µg
   Buy from Supplier
mouse anti-human fabp3 (1e5-c5-g10)  (RayBiotech)
N/A
Mouse anti-Human FABP3 Antibody
   Buy from Supplier
mouse monoclonal anti-human human complement component c5 and c5a  (Angio-Proteomie)
N/A
   Buy from Supplier

Image Search Results


(A) Complement C5-9 fixation on CS2 pRBCs was tested by flow cytometry following opsonization with either antibodies from a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs) or 6 Australian malaria non-exposed donors in the presence of NS. Complement fixation is presented as the average gMFI of each sample tested in duplicate and the red line represents the median gMFI for all samples tested in each category. (B) Correlation between complement C5-9 fixation and C1q/C3 fixation tested on a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs). (C) Complement-mediated pRBC killing/lysis was examined by culturing CS2 pRBCs opsonized with antibodies from PNG pregnant women (n=7) in the presence of normal serum, heat-inactivated serum or no-added serum and measuring parasitaemia by flow cytometry after two growth cycles. Data are presented as the average parasitaemia of each sample run in triplicate over 3 independent experiments. The dotted red line represents the median parasitaemia of CS2 pRBCs cultured in the absence of either PNG or Australian malaria non-exposed antibodies and NS or HIS. Comparisons were made using Mann-Whitney U-test.

Journal: medRxiv

Article Title: Reduced risk of placental parasitaemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women

doi: 10.1101/2021.06.02.21258254

Figure Lengend Snippet: (A) Complement C5-9 fixation on CS2 pRBCs was tested by flow cytometry following opsonization with either antibodies from a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs) or 6 Australian malaria non-exposed donors in the presence of NS. Complement fixation is presented as the average gMFI of each sample tested in duplicate and the red line represents the median gMFI for all samples tested in each category. (B) Correlation between complement C5-9 fixation and C1q/C3 fixation tested on a subset of 7 PNG donor samples (with moderate to high C1q/C3 fixing activity on CS2 pRBCs). (C) Complement-mediated pRBC killing/lysis was examined by culturing CS2 pRBCs opsonized with antibodies from PNG pregnant women (n=7) in the presence of normal serum, heat-inactivated serum or no-added serum and measuring parasitaemia by flow cytometry after two growth cycles. Data are presented as the average parasitaemia of each sample run in triplicate over 3 independent experiments. The dotted red line represents the median parasitaemia of CS2 pRBCs cultured in the absence of either PNG or Australian malaria non-exposed antibodies and NS or HIS. Comparisons were made using Mann-Whitney U-test.

Article Snippet: Pigmented trophozoite stage parasites at ∼10% parasitaemia and 0.5% haematocrit were incubated with 25% NS and 10% antibodies from PNG pregnant women or Australian malaria non-exposed donors for 1 hour at 37°C. pRBCs were then washed in 0.5% BSA in PBS and C1q, C3 and C5-9 detected by staining with polyclonal rabbit anti-human C1q, goat anti-human C3 or monoclonal mouse anti-human C5-9 antibodies followed by respective polyclonal Alexa-488 conjugated goat anti-rabbit, rabbit anti-goat or goat anti-mouse antibodies. pRBCs were detected by staining with ethidium bromide (Bio-Rad) at 1/1000 dilution.

Techniques: Flow Cytometry, Activity Assay, Lysis, Cell Culture, MANN-WHITNEY